Characteristic Clinicians and physician researchers | Have never heard of N (%) | Have heard of N (%) | Would like to participate in N (%) | Have strong interest in N (%) | Have participated in N (%) | Σ N (%) | χ2, p value |
---|---|---|---|---|---|---|---|
(a) All participants | |||||||
EULAR online course | 55 (10) | 78 (14) | 112 (21) | 125 (23) | 174 (32) | 544 (100) | NA |
EULAR online course on Connective Tissue Diseases | 79 (15) | 146 (27) | 146 (27) | 155 (29) | 18 (3) | ||
EULAR/EUSTAR online course on SSc | 87 (16) | 161 (30) | 146 (27) | 122 (22) | 28 (5) | ||
EULAR ultrasound online course | 93 (17) | 134 (25) | 117 (22) | 152 (28) | 48 (9) | ||
EULAR postgraduate course | 118 (22) | 125 (23) | 107 (20) | 121 (22) | 73 (13) | ||
EULAR epidemiology course | 141 (26) | 178 (33) | 110 (20) | 84 (15) | 31 (6) | ||
ACR/EULAR exchange programme | 208 (38) | 142 (26) | 89 (16) | 98 (18) | 7 (1) | ||
EUREKA course of Translational Medicine | 277 (51) | 130 (24) | 83 (15) | 46 (9) | 8 (2) | ||
EUSTAR SSc course | 187 (34) | 139 (26) | 92 (17) | 98 (18) | 28 (5) | ||
EULAR course on capillaroscopy | 127 (23) | 159 (29) | 114 (21) | 121 (22) | 23 (4) | ||
EULAR ultrasound course | 78 (14) | 112 (21) | 107 (20) | 197 (36) | 50 (9) | ||
(b) EULAR online course—clinical position | |||||||
Medical student | 3 (38) | 2 (25) | 3 (38) | 0 (0) | 0 (0) | 8 (100) | <0.001 |
Trainee (internal m.) | 6 (14) | 9 (21) | 11 (25) | 9 (21) | 9 (21) | 44 (100) | |
Trainee (rheum.) | 32 (11) | 34 (11) | 54 (18) | 79 (26) | 102 (34) | 301 (100) | |
Young consultant | 14 (7) | 33 (17) | 44 (23) | 37 (19) | 63 (33) | 191 (100) | |
(c) EULAR postgraduate course—clinical position | |||||||
Medical student | 4 (50) | 4 (50) | 0 (0) | 0 (0) | 0 (0) | 8 (100) | <0.001 |
Trainee (internal m.) | 20 (45) | 7 (16) | 9 (20) | 5 (11) | 3 (7) | 44 (100) | |
Trainee (rheum.) | 74 (25) | 65 (22) | 60 (20) | 73 (24) | 29 (10) | 301 (100) | |
Young consultant | 20 (11) | 49 (26) | 38 (20) | 43 (23) | 41 (22) | 191 (100) | |
(d) EULAR online course—country of origin | |||||||
Group 1 | 27 (12) | 40 (18) | 50 (23) | 40 (19) | 65 (29) | 222 (100) | 0.118 |
Group 2 | 23 (10) | 31 (14) | 45 (20) | 56 (25) | 74 (32) | 229 (100) | |
Group 3 | 4 (4) | 7 (8) | 17 (19) | 29 (32) | 35 (38) | 92 (100) | |
(e) EULAR postgraduate course—country of origin | |||||||
Group 1 | 79 (35) | 59 (27) | 33 (15) | 39 (18) | 12 (5) | 222 (100) | <0.001 |
Group 2 | 32 (14) | 53 (23) | 51 (22) | 54 (24) | 39 (17) | 229 (100) | |
Group 3 | 7 (8) | 12 (13) | 23 (25) | 28 (30) | 22 (24) | 92 (100) |
(a–e) Total sample with N=656 participants of whom 544 responded to this part of the survey. Values are expressed as absolute numbers and percentages in brackets as N (%).
(a) Analysis with all responses. (b, c) Analysis on categorisation of participants according to clinical position. (d, e) Analysis on categorisation of participants according to country of origin. Countries allocated to groups 1–3 according to the GDP per capita 2014. Group 1: Norway, Switzerland, Denmark, Sweden, Ireland, the Netherlands, Austria, Belgium, Germany, UK, France, Italy, Andorra; Group 2: Spain, Cyprus, Malta, Slovenia, Portugal, Greece, Estonia, Czech Republic, Slovakia, Lithuania, Latvia, Poland, Hungary; Group 3: Croatia, Russia, Turkey, Romania, Belarus, Azerbaijan, Bulgaria, Serbia, Albania, Georgia, Ukraine, Moldova.
ACR, American College of Rheumatology; EULAR, European League Against Rheumatism; EUSTAR, European Scleroderma Trial and Research Organization; GDP, gross domestic product; internal m, internal medicine; NA, not applicable; rheum, rheumatism; SSc, systemic sclerosis.